You are on page 1of 8

Countries & Sectors To Focus On

• Canada • BFSI
• USA • Healthcare
• Brazil • Insurance
• UAE • Media &
• India Communication
• Australia • Retail
• China • Technology
• Malaysia • Travel & Hospitality
• Phillipines • Govt
Healthcare
China - HealthCare
• But the Chinese government's pressure to keep drug prices low could mean potential risks for
multinationals, she said.
• Other multinational drug firms, such as Sanofi, have also been probed by Chinese authorities.
• "The anti-corruption investigations in the health care sector serve the reform goal to rein in
costs of drugs and health care products, which are believed to be critical to stimulate
domestic consumption," Boynton said.
• Following the highly public scandal, GSK announced last year that it would lower the prices of
its products in China.
• he heightened scrutiny of the health care sector, which is expected to continue in the coming
months, will make the China market more complex. It is important for foreign companies to
focus on their compliance efforts to minimise risks," she said.
• "Yet most, if not all of these additional investments are being built on top of a weak
foundation. Doctors are chronically overworked and underpaid. Hospital administrators
struggle to meet shortfalls between government reimbursement and increasing costs."
USA – Healthcare

• Rising customer expectations: The commercial environment is


getting harsher, as healthcare payers impose new cost constraints
on healthcare providers and scrutinise the value medicines offer
much more carefully. They want new therapies that are clinically
and economically better than the existing alternatives, together
with hard, real-world outcomes data to back any claims about a
medicine’s superiority.
• Poor scientific productivity: Pharma’s output has remained at a
stable level for the past decade. Using the same discovering and
developing processes, there’s little reason to think its productivity
will suddenly soar.
• Cultural sclerosis: The prevailing management culture, mental
models and strategies on which the industry relies are the same
ones it’s traditionally relied on, even though they’ve been eclipsed
by new ways of doing business.
Latin America HealthCare
MENA Challanges
• Challenges -Brand promotion
• Fragmented regulatory procedures
• Preferential treatment for local producers
• Lower quality perception limiting generic penetration
• ■ Each country in the region has its own registration procedures -
Mutual recognition developing in the GCC -Certain health
authorities are considered as “standards “ for other authorities
which will expedite their approving the product ■ Stringent
regulation requirements represent a significant barrier to entry in
countries like Saudi Arabia, Egypt and Morocco ■ Registration times
stretch from six months up to 3-4 years ■ Most markets favor local
manufacturers by a variety of methods -faster registration times -
preferential pricing -prohibition of importation of generic versions
of locally manufactured products
Australia - Healthcare
• Government spending
• Health care is one of the largest industries in the world. However, challenging economic
conditions are making it difficult for governments in many of the world’s regions to
devote the necessary financial resources needed to handle expanding health care
demands—especially when they are coupled with ever-rising costs.
• Health care reform
• To resolve this challenge, many countries are taking a broad approach to cost
containment, including:
• Implementing comprehensive health care reform
• Exploring alternative financial models

• Drug price controls


• Amid the reform-driven shift to outcomes focused, value-based payment and
reimbursement systems, numerous countries are instituting reform-driven drug price
controls. Drug manufacturers will continue to be pressured to justify the cost of their
products42 based on, among other things, the product’s comparative effectiveness
against similar offerings.
• Download the report for a full list of references.
Indian HealthCare